Myers K, Silverberg JI, Parasuraman S, Pierce A, Eichenfield LF, Poulos C. Treatment preferences among patients with mild-to-moderate atopic dermatitis. J Dermatolog Trea. 2023 Dec;34(1):2215356. doi: 10.1080/09546634.2023.2215356.
Kwatra SG, Lio P, Weidinger S, Calimlim B, Ladizinski B, Vigna N, Botha W, Mansfield C. Patient preferences for atopic dermatitis treatments: a discrete choice experiment. J Dermatolog Trea. 2023 Dec 1;34(1):2222201. doi: 10.1080/09546634.2023.2222201
Mellor R, Kearnes M, Lancaster K, McLauchlan L, Ritter A. Established tables and emergent huddles: exploring the processes of participation associated with the policy changes to opioid pharmacotherapy treatment in Australia in the context of COVID-19. Contemp Drug Probl. 2022 Sep 8;49(4):385-404. doi: 10.1177/00914509221123001
Skajaa N, Adelborg K, Horvath-Puho E, Rothman KJ, Henderson VW, Thygesen LC, Sorensen HT. Stroke and risk of mental disorders compared with matched general population and Myocardial infarction comparators. Stroke. 2022 Jul;53(7):2287-98. doi: 10.1161/STROKEAHA.121.037740
Jia X, Zhao Y, Carrico J, Brodtkorb T-H, Mendelsohn AM, Lowry S, Feldman S, Wu JJ, Armstrong AW. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. J Dermatolog Trea. 2022 Mar;33(2):740-8. doi: 10.1080/09546634.2020.1773382
Ervin C, Crawford R, Evans E, Feldman SR, Zeichner J, Zielinski M, Cappelleri JC, DiBonaventura M, Takiya L, Myers DE. Patient and caregiver preferences on treatment attributes for atopic dermatitis. J Dermatolog Trea. 2021 Oct 6;1-9. doi: 10.1080/09546634.2021.1940810
Feldman SR, Poulos C, Gilloteau I, Mange B, Boehm K, Boeri M, Naatz M, Augustin M. Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany. J Dermatolog Trea. 2021 Feb 3;1-10. doi: 10.1080/09546634.2020.1839007
Martin SA, Brown TM, Fehnel S, Deal LS, Katz EG, Chiou CF. The atopic dermatitis itch scale: development of a new measure to assess pruritus in patients with atopic dermatitis. J Dermatolog Trea. 2020 Aug;31(5):484-30708. doi: 10.1080/09546634.2020.1713971
Wu JJ, Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry A, Feldman SR, Armstrong A. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. J Dermatolog Trea. 2020 Apr 1;1-8. doi: 10.1080/09546634.2019.1698700
Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Barbe F, Castan MT, Seminario MA, Pujol J, Alseda M. Prevalence and characteristics of chronic obstructive pulmonary disease in non-smokers. Aten Primaria. 2019 Dec;51(10):602-9. doi: 10.1016/j.aprim.2017.10.012
Giner-Soriano M, Teixido C, Marsal JR, Diez O, Pera H, Vlacho B, Morros R, working group for the clinical trial IJG-KOH-2014. Randomized placebo-controlled clinical trial on efficacy and safety of topical 10% Potassium hydroxide for molluscum contagiosum treatment in children. J Dermatolog Trea. 2019 Dec;30(8):750-6. doi: 10.1080/09546634.2019.1573305
Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Barbe F, Castan MT, Seminario MA, Pujol J, Alseda M. Comment: Prevalence and characteristics of chronic obstructive pulmonary disease in non-smokers. Aten Primaria. 2019 Nov;51(9):589-90.
Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE. Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Trea. 2017 Sep;28(6):492-9. doi: 10.1080/09546634.2017.1307464
Korman NJ, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Nyirady J, Williams N, Mordin M, Tyring S. Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. J Dermatolog Trea. 2017 Aug;28(5):384-9.
Cruz-Esteve I, Marsal-Mora JR, Galindo-Ortego G, Galvan-Santiago L, Serrano-Godoy M, Ribes-Murillo E, Real-Gatius J, en representacion del grupo de investigacion GRETAP. Potentially inappropriate prescribing in older Spanish population according to STOPP/START criteria (STARTREC Study). Aten Primaria. 2017 Mar;49(3):166-76. doi: 10.1016/j.aprim.2016.02.013
Jeyakumar G, Tu JV, Austin PC, Hall R, Jin A, Manuel D, Silver FL, Swartz R, Chu A, Khan AM, Kapral MK. Rural-urban differences in stroke incidence, mortality and risk factor prevalence in Ontario. Poster presented at the American Heart Association/American Stroke Association 2017 International Stroke Conference; February 21, 2017. Houston, TX. [abstract] Stroke. 2017 Feb; 48(Suppl_1):180. doi: 10.1161/str.48.suppl_1.wp180
Pariser D, Schenkel B, Carter C, Farahi K, Brown TM, Ellis CN. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. J Dermatolog Trea. 2016 Jan;27(1):19-26. doi: 10.3109/09546634.2015.1044492
Montserrat-Capdevila J, Godoy P, Marsal JR, Barbe-Illa F. Risk factors for mortality in patients with chronic obstructive pulmonary disease. Aten Primaria. 2015 Oct;47(8):498-504. doi: 10.1016/j.aprim.2014.11.004
Shah S, Murthy S, Karanth S, Bershad EM, Venkatasubba Rao CP, Suarez JI. Treatment of ischemic stroke with recombinant tissue plasminogen-activator in pregnancy: a population study. Poster presented at the International Stroke Conference 2014; February 2014. San Diego, CA. [abstract] Stroke. 2014 Feb; 45(Suppl 1). doi: doi.org/10.1161/str.45.suppl_1.wp61Stroke. 2014;45:AWP61
Murthy S, Shah S, Karanth S, Shastri A, Bershad E, Suarez JI. Clinical outcomes following thrombolysis for acute ischemic stroke in patients with primary brain tumors: a nationwide population study. Poster presented at the International Stroke Conference 2014; February 2014. San Diego, CA. [abstract] Stroke. 2014 Feb; 45(Suppl 1). doi: 10.1161/str.45.suppl_1.tmp14Stroke. 2014;45:ATMP14
Murthy S, Shah S, Karanth S, Shastri A, Bershad E, Suarez JI. Clinical outcomes following thrombolysis for acute ischemic stroke in patients with systemic malignancy: a nationwide case-control study. Poster presented at the International Stroke Conference 2014; February 2014. San Diego, CA. [abstract] Stroke. 2014 Feb; 45(Suppl 1).
Murthy SB, Karanth S, Shah S, Shastri A, Rao CP, Bershad EM, Suarez JI. Thrombolysis for acute ischemic stroke in patients with cancer: a population study. Stroke. 2013 Dec;44(12):3573-6. doi: 10.1161/STROKEAHA.113.003058
Puente D, Zabaleta-Del-Olmo E, Pueyo MJ, Salto E, Marsal JR, Bolibar B. Cigarette smoking prevalence and associated factors in secondary school children in Catalunya. Aten Primaria. 2013 Jun;45(6):315-23. doi: 10.1016/j.aprim.2012.12.007
Earnshaw SR, Jackson D, Farkouh R, Schwamm L. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis. Stroke. 2009 May 1;40(5):1710-20.
Earnshaw SR, Jackson DL, Farkouh RA, Schwamm LH. Cost-effectiveness of MRI-based selection of patients for intravenous thrombolysis. Poster presented at the 2009 International Stroke Conference; February 2009. San Diego, CA. [abstract] Stroke. 2009 Apr; 40(4):E192-3.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006 Nov 28;37(11):2751-8.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage. Poster presented at the 2006 International Stroke Conference; February 17, 2006. [abstract] Stroke. 2006 Nov; 37(11):2751.
Djousse L, Rothman KJ, Cupples LA, Arnett DK, Ellison RC. Relation between serum albumin and carotid atherosclerosis the NHLBI family heart study. Stroke. 2003 Jan 1;34(1):53-7.
Clarkson TB, Anthony MS, Mikkola TS, St. Clair RW. Comparison of tibolone and conjugated equine estrogens effects on carotid artery atherosclerosis of postmenopausal monkeys. Stroke. 2002 Nov;33(11):2700-3.